Serum IL-1β can be a biomarker in children with severe persistent allergic rhinitis
Serum IL-1β can be a biomarker in children with severe persistent allergic rhinitis
复制标题
DOI：
10.1186/s13223-019-0368-8
复制
发表时间：
2019-09-18
影响因子：
2.7
通讯作者：
Lee, Jiho
中科院分区：
文献类型：
--
作者：
Han, Myung Woul;Kim, Song Hee;Lee, Jiho
背景变应性鼻炎(AR)是全球最常见的疾病之一，通常持续终生。在本研究中，我们旨在确定炎性生物标志物的表达是否与儿童变应性鼻炎的严重程度以及与哮喘或其他过敏性疾病的共病有关。方法采用皮肤点刺试验检测18种变应原对变应性鼻炎的诊断。检测血中嗜酸性粒细胞和免疫球蛋白E(IgE)水平。我们根据病情的严重程度将患者分为2组：1组[间歇性AR(IAR)或轻度持续性AR(PAR)]和2组(中到重度PAR)。采用酶联免疫吸附试验(EL ISA)检测血清中炎症标志物的表达，同时检测血清中caspase-1、IL-1β、CCL-11、CCL-24和IL-33的表达。此外，我们还分析了临床变量与生物标志物(嗜酸性粒细胞计数、IL-1β和CCL-24)的表达以及AR严重程度之间的相关性。结果中、重度PAR患者外周血嗜酸性粒细胞计数、炎性小体活化标志物IL-1β、CCl-24均显著升高(p=0.008，p=0.003，p=0.039)。此外，哮喘活动期患者外周血嗜酸粒细胞计数、IL-1β和CCL-24的表达明显高于无活动期哮喘患者。单因素分析显示，同胞变应性鼻炎、父亲变应性鼻炎、嗜酸性粒细胞高表达、IL-1β、CCL-24、活动期哮喘史、特应性疾病史与AR的严重程度相关。多因素分析显示，只有父亲的变应性鼻炎和IL-1β的高表达是中重度PAR的显著危险因素，风险分别增加6.4%和4.7%(p=0.011和p=0.030)。结论：本研究首次提供了生物活性IL-1β过度释放可能促进重度PAR炎症反应的证据。这表明IL-1β可以作为活动性变态反应性疾病的生物标志物，如AR、哮喘和特应性。此外，这一发现表明，IL-1B应该作为严重的PAR和其他过敏性疾病的治疗靶点进行研究。
Background Allergic rhinitis (AR) is one of the most common diseases globally and usually persists throughout life. In the present study, we aimed to determine whether the expression of inflammatory biomarkers has a relationship with the severity of allergic rhinitis and with comorbid asthma or other allergic diseases in children. Methods For diagnosis of AR, the skin prick test was performed to measure the responses to 18 allergens. Blood levels of eosinophils and immunoglobulin E (IgE) were examined. We classified the patients into 2 groups based on the severity of the condition as Group 1 [intermittent AR (IAR) or mild persistent AR (PAR)] and Group 2 (moderate to severe PAR). To determine the expression of inflammatory biomarkers, in serum and several biomarkers (caspase-1, IL-1 beta, CCL-11, CCL-24 and IL-33) were measured in the serum using enzyme-linked immunosorbent assay (ELISA). Additionally, we analyzed the correlation between clinical variables and the expression of biomarkers (eosinophils count, IL-1 beta and CCL-24) and the severity of AR. Results We found that eosinophils count, IL-1 beta, a marker of activation of inflammasomes, and CCL-24 were significantly increased in the moderate to severe PAR group (p = 0.008, p = 0.003, p = 0.039). Additionally, the expressions of eosinophil count, IL-1 beta and CCL-24 were significantly higher in patients with active asthmatic symptoms than in those without these conditions. On univariate analysis, allergic rhinitis in sibling, paternal allergic rhinitis, high expression of eosinophils count, IL-1 beta and CCL-24, history of active asthma and atopy correlated with severity of AR. Multivariate analysis showed only paternal allergic rhinitis and high expression of IL-1 beta as significant risk factors of moderate to severe PAR with 6.4 fold and 4.7 fold-increase in risk, respectively (p = 0.011 and p = 0.030). Conclusion In conclusion, this study provides the first evidence that an excessive release of biologically active IL-1 beta may promote inflammation in severe PAR. It demonstrates that IL-1 beta can be a biomarker for active allergic diseases such as AR, asthma, and atopy. Moreover, this finding suggests that IL-1B should be investigated as a therapeutic target in severe PAR and other allergic diseases.